TRCT
RLAY icon

Tower Research Capital (TRC)’s Relay Therapeutics RLAY Stock Holding History

Tower Research Capital (TRC)’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$362K Buy
19,327
+8,608
+80% +$125K 0.01% 1251
2026
Q1 		$107K Buy
10,719
+10,038
+1,474% +$89.8K ﹤0.01% 2120
2025
Q4 		$5.76K Sell
681
-7,920
-92% -$56.5K ﹤0.01% 4097
2025
Q3 		$44.9K Sell
8,601
-2,964
-26% -$11.3K ﹤0.01% 2613
2025
Q2 		$40K Sell
11,565
-404
-3% -$1.2K ﹤0.01% 3163
2025
Q1 		$31.4K Sell
11,969
-15,159
-56% -$59.4K ﹤0.01% 2575
2024
Q4 		$112K Buy
27,128
+6,078
+29% +$33.1K ﹤0.01% 2090
2024
Q3 		$149K Sell
21,050
-1,190
-5% -$8.89K ﹤0.01% 1900
2024
Q2 		$145K Buy
22,240
+21,829
+5,311% +$149K ﹤0.01% 2318
2024
Q1 		$3.41K Sell
411
-16,989
-98% -$166K ﹤0.01% 4869
2023
Q4 		$192K Buy
17,400
+15,136
+669% +$128K ﹤0.01% 2134
2023
Q3 		$19K Sell
2,264
-8,098
-78% -$87.1K ﹤0.01% 3422
2023
Q2 		$130K Buy
10,362
+5,872
+131% +$73K ﹤0.01% 1868
2023
Q1 		$74K Sell
4,490
-5,916
-57% -$106K ﹤0.01% 2151
2022
Q4 		$156K Buy
10,406
+1,245
+14% +$23.8K 0.01% 1483
2022
Q3 		$205K Sell
9,161
-6,020
-40% -$132K ﹤0.01% 1913
2022
Q2 		$254K Buy
15,181
+12,473
+461% +$267K 0.01% 1604
2022
Q1 		$81K Sell
2,708
-4,901
-64% -$119K ﹤0.01% 2370
2021
Q4 		$234K Sell
7,609
-1,131
-13% -$35.7K ﹤0.01% 1637
2021
Q3 		$276K Buy
8,740
+5,103
+140% +$172K 0.01% 1500
2021
Q2 		$134K Sell
3,637
-20
-0.5% -$659 ﹤0.01% 2192
2021
Q1 		$126K Sell
3,657
-3,427
-48% -$149K ﹤0.01% 2402
2020
Q4 		$295K Buy
7,084
+1,960
+38% +$88.6K 0.01% 1406
2020
Q3 		$218K Buy
+5,124
New +$195K ﹤0.01% 2499

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Tower Research Capital (TRC)'s RLAY Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Relay Therapeutics (RLAY) stake by 80% in Q2 2026, buying an estimated $125K and bringing the position to 19,327 shares worth $362K. The position accounts for 0.01% of the portfolio, ranked #1251.

Tower Research Capital (TRC) first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Tower Research Capital (TRC) held 19,327 shares of Relay Therapeutics worth $362K as of Q2 2026.
  • Tower Research Capital (TRC) bought 8,608 Relay Therapeutics shares in Q2 2026, an estimated $125K.
  • Relay Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1251 holding.
  • Tower Research Capital (TRC) first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.